Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Laufer

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
Expert Opinion on Therapeutic Patents|March 12, 2014
p38 MAPK inhibitors: a patent review (2012 - 2013)Stefanie Bühler, Stefan A Laufer
Expert Opinion on Drug Discovery|May 31, 2021
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancerFlorian Wittlinger, Stefan A Laufer
Journal of Medicinal Chemistry|December 20, 2018
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical BiologyMatthias Gehringer, Stefan A Laufer
Chemmedchem|June 2, 2007
Are MAP kinases drug targets? Yes, but difficult onesSimona Margutti, Stefan A Laufer
British Journal of Experimental Pathology|October 1, 1975
The effect of beta aminoproprionitrile (BAPN) on experimental amyloidosisD Schechter, M Fields, A Laufer
The Journal of Pathology|December 1, 1980
Demonstration of amyloid in murine and human secondary amyloidosis by the immunoperoxidase techniqueN Livni, A Laufer, Y Levo
Pediatric Annals|August 1, 1987
Respiratory syncytial virus infection and cardiopulmonary diseaseD A Laufer, P J Edelson
Current Topics in Medicinal Chemistry|August 20, 2009
Successful structure-based design of recent p38 MAP kinase inhibitorsSolveigh C Karcher, Stefan A Laufer
Journal of Medicinal Chemistry|March 4, 2009
Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical propertiesSolveigh C Karcher, Stefan A Laufer
The Gerontologist|December 1, 1982
From geriatric resident to language professor: a new program using the talents of the elderly in a skilled nursing facilityE A Laufer, W S Laufer
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
Expert Opinion on Therapeutic Patents|March 12, 2014
p38 MAPK inhibitors: a patent review (2012 - 2013)Stefanie Bühler, Stefan A Laufer
Expert Opinion on Drug Discovery|May 31, 2021
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancerFlorian Wittlinger, Stefan A Laufer
Journal of Medicinal Chemistry|December 20, 2018
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical BiologyMatthias Gehringer, Stefan A Laufer
Chemmedchem|June 2, 2007
Are MAP kinases drug targets? Yes, but difficult onesSimona Margutti, Stefan A Laufer
British Journal of Experimental Pathology|October 1, 1975
The effect of beta aminoproprionitrile (BAPN) on experimental amyloidosisD Schechter, M Fields, A Laufer
The Journal of Pathology|December 1, 1980
Demonstration of amyloid in murine and human secondary amyloidosis by the immunoperoxidase techniqueN Livni, A Laufer, Y Levo
Pediatric Annals|August 1, 1987
Respiratory syncytial virus infection and cardiopulmonary diseaseD A Laufer, P J Edelson
Current Topics in Medicinal Chemistry|August 20, 2009
Successful structure-based design of recent p38 MAP kinase inhibitorsSolveigh C Karcher, Stefan A Laufer
Journal of Medicinal Chemistry|March 4, 2009
Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical propertiesSolveigh C Karcher, Stefan A Laufer
The Gerontologist|December 1, 1982
From geriatric resident to language professor: a new program using the talents of the elderly in a skilled nursing facilityE A Laufer, W S Laufer
Pageof 19